The oral semaglutide reduced the occurrence of major adverse cardiovascular events (MACE) by 14% in patients with type 2 ...

The Wegovy maker’s once-daily pill to treat type 2 diabetes has shown it cuts the risk of heart attacks and strokes in ...

Novo Nordisk said on Monday an oral version of its drug semaglutide, helped significantly reduce the risk of cardiovascular ...

As Novo Nordisk’s injectable diabetes-obesity duo Ozempic and Wegovy grab all the limelight, an oral version of the ...

SOUL Trial Results Position Rybelsus as a Game-Changer in Diabetes and Cardiovascular Care, Poised for Expanded U.S. and E.U.

According to new data from the SOUL trial Oral semaglutide reduced MACE by 14% in Type 2 Diabetes patients. Novo Nordisk will ...

In Novo Nordisk’s randomized clinical trial, semaglutide reduced the risk for major adverse cardiovascular events by 14% ...

Novo Nordisk's SOUL trial reveals a 14% reduction in major cardiovascular events with oral semaglutide in patients with type ...

The medicine, which Novo sells as Rybelsus, cut the risk of cardiovascular complications by 14% when added to standard ...

Novo Nordisk on Monday reported the oral version of its drug semaglutide reduced the risk of major adverse cardiovascular events in adults with type 2 diabetes by 14% in a large Phase III trial.

Discover how Novo Nordisk's GLP-1 medication, Rybelsus, reduces major adverse cardiovascular events by 14% in a phase 3 trial, with plans for an expanded label.

Novo Nordisk A/S (NVO) announced Monday the headline results from the SOUL cardiovascular outcomes trial, which achieved its primary ...